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Abstract: An acid mediated annulation reaction for the formation 
of 7a-substituted unnatural pyrrolizidines is described. To reach 
this goal, the pyrroline 3-(3,4-dihydro-2H-pyrrol-5-yl)propan-1-ol 
is reacted with a large variety of isonitriles directly resulting in the 
target compounds. The reaction is operationally simple and toler-
ates air and water, and the resulting pyrrolizidines can be further 
transformed to the corresponding oxidized and reduced deriva-
tives.  
 
Key words: Pyrrolizidines; Isonitriles; Cyclizations; Pyrrolines. 
Pyrrolizidines constitute a privileged ring structure in 
alkaloids, with hundreds of natural products employing 
this motif.1 The utilization of these bicyclic N–
heterocycles in drug discovery has been hampered by 
their well-known in vivo oxidation to the corresponding 
pyrrole derivatives, which can undergo undesired off-
target reactions (Figure 1).2 One way of preventing this 
aromatization involves quaternization by the presence of 
an additional substituent on the 7a-position.  
  
Figure 1. Substitution at the 7a-position in pyrrolizidines prevents 
oxidation to the pyrrole derivative. 
 
Interestingly, among the many approaches to such heter-
ocycles, there are only few methods reported in the liter-
ature to prepare these 7a-substituted pyrrolizidines car-
boxamides.3 In the context of our research on natural 
products as lead structures inducing neurite outgrowth,4 
we discovered a reaction that yields 7a-substituted pyr-
rolizidines such as 1 from pyrroline 2 and isonitriles 3 
(Figure 2). Related structures are the mixed α7-nicotinic 
receptor antagonist 4, recently identified by Reymond 
and coworkers5, commercially used antiarrhythmic agent 
pilsicainide 56, and the muscarinic antagonist 6 identified 
by Suzuki et al.3b Compounds such as 1 are regioisomer-
ic towards 4 but are potentially interesting structures for 
medicinal chemistry and drug discovery. To the best of 
our knowledge, up to this point, there is no method re-
ported for the direct preparation of pyrrolizidine-7a-
carboxamides. For the construction of the pyrrolizidine 
building block, isonitriles serve as C nucleophiles at the 
C(7a)-position on a putative pyrrolizidinium intermedi-
ate. In this study, we report on a method for the prepara-
tion of pyrrolizidine-7a-carboxamides from pyrroline 
and isonitrile precursors. 
Previous work documented in the literature on a series of 
quinolines and naphthalenes with a 1-
azabicyclo[3.3.0]octane moiety required multi-step se-
quences for their preparation.3a Instead of installing an 
ester on the 7a-position and further peptide coupling, our 
reaction contains a masked amide functionality by using 
isonitriles.  
 
Figure 2. 7a-Substituted pyrrolizidines present lead structures in 
neuroscience and drug discovery 
 
Isonitriles have been shown to serve as useful building 
blocks for the synthesis of complex molecular targets 
especially in multicomponent reactions such as Ugi- or 
the Passerini reactions.7 For example, isonitriles have 
been shown to react with pyrrolines or piperideines and 
carboxylic acids in an Ugi-3-component reaction to sub-
stituted proline or homoproline derivatives.8 Initial ex-
periments were carried out with pyrroline 2 carrying a 
primary hydroxyl group in the side chain.  
 
Scheme 1. Preparation of pyrroline 2 from 2-methyl-1-pyrroline and 
ethylene oxide.  
The precursor 2 was previously synthesized9 via a multi-
step procedure from 4-benzyloxybutyric acid ethyl ester 
7 (Scheme 1). As an improvement, we were able to di-
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rectly react 2-methyl-1-pyrroline with LDA and ethylene 
oxide to the pyrroline 2 in one step from commercially 
available starting materials.10 Initial experiments identi-
fied weak Brønsted acids as suitable catalysts for the 
reaction of pyrroline 2 and isonitriles 3 to deliver pyrrol-
izidine-7a-carboxamides 1 in acceptable yields. Best 
results for this transformation were obtained with tertiary 
amine hydrochloride salts, as secondary ammonium salts 
as well as pyridinium chloride delivered the product in 
lower yield. The reaction temperature required rather 
high boiling solvents from which toluene was identified 
as optimal reaction medium. After further optimization, 
the best acid for this transformation turned out to be 
Et3N·HCl.11 Heating under reflux in toluene was neces-
sary, as at lower temperature no or very little conversion 
of the starting material was observed. With these opti-
mized conditions in hand, we investigated the scope and 
limitations of this method. The reaction was found to 
tolerate a wide scope of substrates (Scheme 2). Aromatic 
isonitriles resulted in good to moderate yields depending 
on their electronic properties. The reaction with electron 
donating isonitriles gave the products 9, 10, 11 and 12 in 
higher yields than rather electron poor isonitriles which 
delivered the products 13, 14, 15 and 16.12 Surprisingly, 
the sterically demanding example 17 was observed in 
higher yield than product 18 from the reaction with phe-
nyl isonitrile. A reason for this might be the positive 
inductive effect of the methyl group in the para-, and of 
the phenyl group in the ortho-position of the aromatic 
ring. Aliphatic isonitriles were also tolerated in this reac-
tion, albeit at lower yield. For example, compound 19 
bearing a morpholine ring was obtained in low yield. In 
contrast, unprotected phenols such as 20 or benzyl sub-
stituted pyrrolizidine-carboxamide 21 could be obtained 
in good yield. Further, the sterically more demanding α-
methylbenzyl isocyanide gave product 22 in lower yield 
than benzyl isocyanide indicating that steric factors in-
fluence the outcome of the reaction to some extent. On 
average the best yields were obtained using isocyanoace-
tates which can be easily prepared from the correspond-
ing amino acid esters using a known literature method.13 
In this respect, the highest yield was obtained for the 
tryptophane related product 23 as well as for valine de-
rivative 24. Additionally, the reaction towards pyrroliz-
idine 24 was performed using 10 equivalents of water 
and product formation was still observed, albeit in lower 
yield (69% to 45%). Aromatic (to deliver product 25), as 
well as aliphatic amino acids containing heteroatoms (to 
deliver products 26 and 27) were also reacted in good 
yields. Unfortunately, these substrates suffered from 
complete racemization under the reaction conditions as 
has been observed before for isocyanoacetates due to 
their α-C-H acidity (pKa = 9-11).13,14 Complete racemi-
zation occurs already on the isonitrile precursors, so that 
full racemization is observed before product formation. 
For pyrrolizidine 22, however, no racemization was 
observed. Extending this method to pyrroline 28 carrying 
a tertiary hydroxy group in the side chain, pyrrolidine 
derivative 30 as a 2.1:1 mixture of prenylated 
Scheme 2. Scope of isonitriles for the construction of pyrrolizidine-
7a-carboxamides. 
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Scheme 3. Formation of pyrrolidines from pyrrolines and isonitriles. 
pyrrolidine and its Δ3,4 isomer 31 is obtained instead of 
pyrrolizidine formation (Scheme 3). Mechanistically, 
formation of the pyrrolizidine derivatives might proceed 
via a pyrrolizidinium intermediate.15 A mechanistic in-
vestigation of these reactions is currently underway in 
our laboratories.  
As an extension of this method, we were able to further 
functionalize the pyrrolizidine core through oxidation on 
the 3-position with a procedure developed by Schäfer 
and coworkers using benzyl(triethyl)ammonium per-
manganate.16 In this report, the transformation has been 
applied to simple long-chain alkyl amines as well as 
N,N-alkylanilines. A direct oxidation on the 3-position of 
the pyrrolizidine core has, to the best of our knowledge, 
not been reported so far. As a mild oxidant, ben-
zyl(triethyl)ammonium permanganate delivers the 3H-
pyrrolizin-3-one product 32 in good yield,  allowing 
rapid access to these biologically relevant structures.17 
Additionally, the tertiary nitrogen atom can be oxidized 
with m-CPBA to furnish N-oxides such as 33, an im-
portant motif of natural products such as the verticillatin 
alkaloids18 as these dipoles are also the oxidized product 
of a self-defense mechanism of certain species against 
toxic pyrrolizidines.19 Alternatively, the amide function-
ality of the pyrrolizidine-7a-carboxamide can be reduced 
to diamine 34 in quantitative yield.20 These structures 
have been identified to show binding affinities for the 
central muscarinic cholinergic receptor and therefore 
represent lead structures for the treatment of neuro-
degenerative diseases.21 
In summary, a method for the direct preparation of 
pyrrolizidine-7a-carboxamides from imines and isoni-
triles has been described. The reaction allows access to 
these biologically relevant structures using aromatic 
isonitriles as well as isocyanoacetates. Generally, the 
reaction with electron rich isonitriles furnished the prod-
uct in higher yield than with electron deficient precur-
sors. In addition, isocyanoacetates were found to be 
excellent substrates, although racemization occurred 
during the reaction. Finally, pyrrolizidine-7a-
carboxamides have been shown to be readily trans-
formed by oxidation or reduction. Extension of this 
method to biologically active compounds such as musca-
rinic agonists are underway in our laboratories and will 
be reported in due course. 
 
  
Scheme 4.  Further transformations to biologically active lead structures. 
 
Reactions were performed under argon in oven-dried 
glassware. Solvents used for chemical transformations 
were either puriss. quality or dried by filtration through 
activated aluminum oxide under nitrogen (H2O content < 
10 ppm, Karl-Fischer titration). Yields refer to purified, 
dried and spectroscopically pure compounds. Flash 
chromatography was performed using silica gel 60 (230-
240 mesh) from Fluka or activated basic aluminium 
oxide (58 Å pore size) from Sigma-Aldrich using a 
forced flow eluent at 0.1-0.3 bar pressure. 
3-(3,4-dihydro-2H-pyrrol-5-yl)propan-1-ol (2) 
Diisopropylamine (6.12 mL, 43.0 mmol, 1.20 equiv.) 
was dissolved in anhydrous THF (12 mL) and cooled to -
78°C. n-BuLi (25 mL of 1.6 mol·L-1 solution in hexane, 
40.0 mmol, 1.10 equiv.) was added dropwise and stirred 
for 40 min at -78°C. 2-Methyl-1-pyrroline (3.4 mL, 36.0 
mmol, 1.00 equiv.) was added and the reaction mixture 
was stirred for 1 h at -78°C. Ethylene oxide (16 mL, 
40.0 mmol, 2.5 mol·L-1 solution in THF) was added at -
78°C and the mixture was stirred for 5 h. The reaction 
was quenched with aqueous sat. NaHCO3 solution and 
the layers were separated. The aqueous layer was ex-
tracted with EtOAc (3x) and the combined organic layers 
were dried over MgSO4. Evaporation of the solvents 
gave the crude product as a yellow oil. The residue was 
purified by distillation (b.p. 55°C, 9.4·10-3 mbar) to ob-
tain a colorless oil, which turned yellow upon standing. 
(2.44 g, 19 mmol, 53% yield). 1H NMR (250 MHz, 
CDCl3) δ = 3.87–3.75 (m, 2H), 3.73–3.65 (m, 2H), 2.57–
2.38 (m, 4H), 1.96–1.82 (m, 4H) ppm. 13C NMR (101 
MHz, CDCl3) δ = 179.57, 63.10, 60.43, 38.31, 32.58, 
28.62, 22.68 ppm. FTIR (neat) ν = 2965, 2921, 2854, 
1619, 1431, 1303, 1267, 1194, 1113 cm-1. HR-MS (ESI): 
C7H14NO+ [M+H]+: calculated: 128.1070 found: 
128.1070. 
 
 
General procedure for the synthesis of pyrrolizidines 
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Imine 2 (0.47 mmol, 1.00 equiv.) and isonitrile (0.47 
mmol, 1.00 equiv.) were dissolved in dry toluene (3.6 
mL) and Et3N·HCl (0.94 mmol, 2.00 equiv.) was added. 
The suspension was heated under reflux and the reaction 
was monitored by TLC. The reaction mixture was dilut-
ed with water, the layers were separated and the aqueous 
layer was extracted using Et2O (2x). The combined or-
ganic layers were dried over MgSO4. The solvents were 
removed in vacuo and the residue was purified by flash 
column chromatography. 
 
N-(4-Methoxyphenyl)tetrahydro-1H-pyrrolizine-
7a(5H)-carboxamide (9) 
Purification by column chromatography on silica gel 
using CH2Cl2:MeOH = 40:1 (Rf = 0.19). The product 
was isolated as a yellow solid in 68% yield (83 mg, 0.32 
mmol). 1H-NMR (400 MHz, CDCl3) δ = 9.94 (s, 1H), 
7.62–7.46 (m, 2H), 6.93–6.79 (m, 2H), 3.79 (s, 3H), 
3.24–3.11 (m, 2H), 2.71–2.60 (m, 2H), 2.36–2.24 (m, 
2H), 1.91–1.67 (m, 6H) ppm. 13C-NMR (101 MHz, 
CDCl3) δ = 175.65, 156.10, 131.56, 120.81, 114.20, 
78.38, 56.01, 55.65, 37.36, 26.39 ppm. FTIR (neat) ν = 
3256, 2960, 2869, 1678, 1516, 1245 cm-1. HR-MS (ESI): 
C15H21N2O2+ [M+H]+: calculated: 261.1598 found: 
261.1601. M.p. = 84°C. 
 
N-(4-(Methylthio)phenyl)tetrahydro-1H-pyrrolizine-
7a(5H)-carboxamide (10) 
Purification by column chromatography on basic alumi-
num oxide using EtOAc:pentane = 1:6 (Rf = 0.32). The 
product was obtained as a brown oil in 47 % yield (61 
mg, 0.22 mmol). 1H NMR (400 MHz, CDCl3) δ = 10.05 
(s, 1H), 7.60–7.51 (m, 2H), 7.30–7.20 (m, 2H), 3.17 
(ddd, J = 10.3, 6.0, 4.6 Hz, 2H), 2.72–2.60 (m, 2H), 2.45 
(s, 3H), 2.33–2.24 (m, 2H), 1.90–1.76 (m, 4H), 1.76–
1.67 (m, 2H) ppm. 13C NMR (101 MHz, CDCl3) δ = 
176.02, 135.99, 132.90, 128.43, 119.92, 78.47, 56.02, 
37.37, 26.38, 17.16 ppm. FTIR (neat) ν = 3245, 2964, 
2938, 2868, 1681, 1505 cm-1. HR-MS (ESI): 
C15H21N2OS+ [M+H]+: calculated: 277.1369 found: 
277.1371. 
 
N-(2,6-Dimethoxyphenyl)tetrahydro-1H-pyrrolizine-
7a(5H)-carboxamide (11) 
Purification by column chromatography on silica gel 
using CH2Cl2:MeOH = 30:1 (Rf = 0.22). The product 
was obtained as a yellow oil in 50 % yield (69 mg, 0.24 
mmol). 1H NMR (400 MHz, CDCl3) δ = 9.26 (s, 1H), 
7.13 (t, J = 8.4 Hz, 1H), 6.57 (d, J = 8.4 Hz, 2H), 3.80 (s, 
6H), 3.21 (dt, J = 10.2, 5.2 Hz, 2H), 2.64 (dt, J = 9.9, 7.1 
Hz, 2H), 2.35 (dt, J = 11.6, 5.4 Hz, 2H), 1.92–1.83 (m, 
4H), 1.83–1.73 (m, 2H) ppm. 13C NMR (101 MHz, 
CDCl3) δ = 176.49, 155.70, 127.19, 115.18, 104.75, 
100.11, 78.47, 56.27, 55.97, 37.22, 26.58 ppm. FTIR 
(neat) ν = 3281, 2959, 2867, 1686, 1593, 1507, 1461, 
1256, 1108 cm-1. HRMS (ESI) Exact mass calculated for 
C16H23N2O3+ [M+H]+: calculated: 291.1703 found: 
291.1704. 
N-(Benzo[d][1,3]dioxol-5-yl)tetrahydro-1H-
pyrrolizine-7a(5H)-carboxamide (12) 
Purification by column chromatography on basic alumin-
ium oxide using EtOAc:pentane = 1:4 (Rf = 0.36). The 
product was obtained as a brown solid in 49 % yield (63 
mg, 0.23 mmol). 1H NMR (400 MHz, CDCl3) δ = 9.97 
(s, 1H), 7.36 (d, J = 2.1 Hz, 1H), 6.89 (dd, J = 8.3, 2.1 
Hz, 1H), 6.74 (d, J = 8.3 Hz, 1H), 5.93 (s, 2H), 3.16 
(ddd, J = 10.3, 5.9, 4.5 Hz, 2H), 2.65 (ddd, J = 10.0, 7.8, 
5.6 Hz, 2H), 2.33–2.23 (m, 2H), 1.90–1.76 (m, 5H), 
1.76–1.69 (m, 1H) ppm. 13C NMR (101 MHz, CDCl3) δ 
= 175.69, 147.91, 143.87, 132.73, 112.21, 108.14, 
101.94, 101.25, 78.41, 56.00, 37.36, 26.39 ppm. FTIR 
(neat) ν = 3238, 2963, 2870, 1676, 1504, 1038 cm-1. HR-
MS (ESI): C15H19N2O3+ [M+H]+: calculated: 275.1390 
found: 275.1389. M.p. = 106–108°C. 
 
N-(Naphthalen-2-yl)tetrahydro-1H-pyrrolizine-
7a(5H)-carboxamide (13) 
Purification by column chromatography basic aluminium 
oxide using EtOAc:pentane = 1:15 (Rf = 0.28). The 
product was isolated as a brown solid in 41% yield (54 
mg, 0.19 mmol).  1H NMR (400 MHz, CDCl3) δ = 10.18 
(s, 1H), 8.25 (d, J = 2.1 Hz, 1H), 7.71 (dd, J = 9.8, 7.4 
Hz, 3H), 7.48 (dd, J = 8.8, 2.2 Hz, 1H), 7.37 (ddd, J = 
8.2, 6.8, 1.4 Hz, 1H), 7.33–7.28 (m, 1H), 3.19–3.11 (m, 
2H), 2.68–2.57 (m, 2H), 2.32–2.23 (m, 2H), 1.84–1.73 
(m, 4H), 1.73–1.66 (m, 2H) ppm. 13C NMR (101 MHz, 
CDCl3) δ = 176.34, 135.59, 134.12, 130.59, 127.76, 
127.65, 126.49, 124.82, 119.75, 115.76, 78.59, 56.08, 
37.43, 26.42 ppm. FTIR (neat) ν = 3237, 3057, 2963, 
2867, 1681, 1524, 1496 cm-1. HR-MS (ESI): 
C18H21N2O+ [M+H]+: calculated: 281.1648 found: 
281.1650.  M.p. = 108–110°C. 
 
N-(4-Bromophenyl)tetrahydro-1H-pyrrolizine-
7a(5H)-carboxamide (14) 
Purification by column chromatography on basic alumin-
ium oxide using EtOAc:pentane = 1:8 (Rf = 0.19). The 
product was isolated as a brown solid in 30% yield (43 
mg, 0.14 mmol). 1H NMR (400 MHz, CDCl3) δ = 10.11 
(s, 1H), 7.54–7.50 (m, 2H), 7.44–7.40 (m, 2H), 3.17 
(ddd, J = 10.3, 6.1, 4.6 Hz, 2H), 2.70–2.62 (m, 2H), 
2.32–2.24 (m, 2H), 1.89–1.78 (m, 4H), 1.77–1.69 (m, 
2H) ppm. 
ppm. 13C NMR (101 MHz, CDCl3) δ = 176.20, 137.23, 
131.97, 120.92, 116.37, 78.51, 56.01, 37.36, 26.36. FTIR 
(neat) ν = 3236, 2965, 2869, 1684, 1503, 1396 cm-1. HR-
MS (ESI): C14H18BrN2O+ [M+H]+: calculated: 309.0597 
found: 309.0600. M.p. = 91°C. 
 
N-(4-Fluorophenyl)tetrahydro-1H-pyrrolizine-
7a(5H)-carboxamide (15) 
Purification by column chromatography on basic alumin-
ium oxide using EtOAc:pentane = 1:8 (Rf = 0.5). The 
product was isolated as a white solid in 41% yield (48 
mg, 0.19 mmol). 1H NMR (400 MHz, CDCl3) δ = 10.06 
(s, 1H), 7.64–7.51 (m, 2H), 7.07–6.95 (m, 2H), 3.17 
(ddd, J = 10.3, 6.1, 4.6 Hz, 2H), 2.66 (ddd, J = 9.9, 7.8, 
5 Article  
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5.4 Hz, 2H), 2.34–2.24 (m, 2H), 1.91–1.78 (m, 4H), 
1.78–1.68 (m, 2H) ppm. 13C NMR (101 MHz, CDCl3) δ 
= 175.97, 159.2 (d, JC-F = 242.7 Hz), 134.29, 120.95, 
120.87, 115.72, 115.50, 78.42, 56.00, 37.35, 26.37 ppm. 
19F NMR (376 MHz, CDCl3) δ =  –122.03 ppm. FTIR 
(neat) ν = 3230, 2965, 2870, 1680, 1513, 1407, 1211 
cm-1. HR-MS (ESI): C14H18FN2O+ [M+H]+: calculated: 
249.1398 found: 249.1399. M.p. = 133-135°C. 
 
N-(4-Ethynylphenyl)tetrahydro-1H-pyrrolizine-
7a(5H)-carboxamide (16) 
Purification by column chromatography on basic alumin-
ium oxide using Et2O:pentane  = 1:3 (Rf = 0.21). The 
product was obtained as a brown oil in 18 % yield (22 
mg, 0.086 mmol). 1H NMR (400 MHz, CDCl3) δ = 
10.17 (s, 1H), 7.63–7.54 (m, 2H), 7.49–7.40 (m, 2H), 
3.24–3.12 (m, 2H), 3.03 (s, 1H), 2.71–2.62 (m, 2H), 
2.33–2.24 (m, 2H), 1.90–1.78 (m, 4H), 1.78–1.67 (m, 
2H) ppm. 13C NMR (101 MHz, CDCl3) δ = 176.25, 
138.58, 133.03, 118.95, 117.22, 83.77, 78.53, 76.62, 
56.01, 37.38, 26.36 ppm. FTIR (neat) ν = 3236, 2931, 
2869, 1680, 1513 cm-1. HR-MS (ESI): C16H19N2O+ 
[M+H]+: calculated: 255.1492 found: 255.1494. 
 
N-(5-Methyl-[1,1'-biphenyl]-2-yl)tetrahydro-1H-
pyrrolizine-7a(5H)-carboxamide (17) 
Purification by column chromatography on silica gel 
using CH2Cl2:MeOH = 20:1 (Rf = 0.28). The product 
was obtained as a white solid in 63% yield (88 mg, 0.28 
mmol). 1H NMR (400 MHz, CDCl3) δ = 10.24 (s, 1H), 
8.27 (d, J = 8.3 Hz, 1H), 7.48–7.41 (m, 2H), 7.41–7.31 
(m, 3H), 7.17 (dd, J = 8.3, 2.1 Hz, 1H), 7.06 (d, J = 2.1 
Hz, 1H), 2.77–2.66 (m, 2H), 2.42–2.33 (m, 2H), 2.34 (s, 
3H), 2.27–2.16 (m, 2H), 1.78–1.52 (m, 6H) ppm. 13C 
NMR (101 MHz, CDCl3) δ = 175.74, 139.00, 133.30, 
132.89, 132.56, 130.47, 129.43, 128.97, 128.62, 127.53, 
120.22, 78.56, 55.47, 37.11, 26.74, 21.01 ppm. FTIR 
(neat) ν = 3208, 2963, 2868, 1681, 1514, 1467 cm-1. HR-
MS (ESI): C21H25N2O+ [M+H]+: calculated: 321.1961 
found: 321.1960. M.p. = 89–91 °C. 
 
N-Phenyltetrahydro-1H-pyrrolizine-7a(5H)-
carboxamide (18) 
Purification by column chromatography on silica gel 
using CH2Cl2:MeOH 40:1 (Rf = 0.41). The product was 
obtained as a yellow solid in 46% yield (50 mg, 0.22 
mmol). 1H-NMR (500 MHz, CDCl3) δ = 10.07 (s, 1H), 
7.61 (dd, J = 8.5, 1.0 Hz, 2H), 7.35– 7.28 (m, 2H), 7.11–
7.05 (m, 1H), 3.22–3.13 (m, 2H), 2.71–2.62 (m, 2H), 
2.34–2.25 (m, 2H), 1.89–1.78 (m, 4H), 1.78–1.69 (m, 
2H) ppm. 13C-NMR (126 MHz, CDCl3) δ = 176.11, 
138.15, 129.06, 123.93, 119.31, 78.47, 56.01, 37.37, 
26.37 ppm. FTIR (neat) ν = 3187, 2961, 2923, 2853, 
1670, 1600, 1510, 1440, 1312 cm-1. HR-MS (ESI): 
C14H19N2O+ [M+H]+: calculated: 231.1492 found: 
231.1494. M.p.: 105–108°C. 
 
 
N-(2-Morpholinoethyl)tetrahydro-1H-pyrrolizine-
7a(5H)-carboxamide (19) 
Purification by column chromatography on basic alumin-
ium oxide using EtOAc (Rf = 0.17). The product was 
obtained as a colorless oil in 32 % yield (41 mg, 0.15 
mmol). 1H NMR (250 MHz, CDCl3) δ = 8.17 (s, 1H), 
3.68 (d, J = 4.5 Hz, 4H), 3.31 (q, J = 6.2 Hz, 2H), 3.07 
(ddd, J = 9.8, 6.5, 4.2 Hz, 2H), 2.62–2.52 (m, 2H), 2.44 
(dd, J = 6.3, 3.4 Hz, 6H), 2.22–2.11 (m, 2H), 1.84–1.60 
(m, 6H) ppm. 13C NMR (101 MHz, CDCl3) δ = 177.74, 
161.24, 77.89, 67.18, 57.68, 55.88, 53.55, 37.17, 35.84, 
26.37 ppm. FTIR (neat) ν = 3326, 2956, 2856, 2811, 
1657, 1512, 1118 cm-1. HR-MS (ESI): C14H26N3O2+ 
[M+H]+: calculated: 268.2020 found: 268.2023. 
 
N-(4-Hydroxyphenethyl)tetrahydro-1H-pyrrolizine-
7a(5H)-carboxamide (20) 
The reaction was performed using the general procedure 
on a 0.145 mmol scale. Purification by column chroma-
tography on silica gel using CH2Cl2:MeOH = 20:1 (Rf = 
0.05). The product was obtained as a white solid in 51 % 
yield (16 mg, 74 µmol). 1H NMR (400 MHz, CDCl3) δ = 
8.11 (s, 1H), 7.04–6.96 (m, 2H), 6.78 (dd, J = 8.4, 1.6 
Hz, 2H), 3.48 (q, J = 6.6 Hz, 2H), 2.96 (dt, J = 10.3, 5.8 
Hz, 2H), 2.72 (t, J = 6.8 Hz, 2H), 2.51 (ddd, J = 9.8, 7.8, 
5.6 Hz, 2H), 2.11–2.01 (m, 2H), 1.70 (m, 4H), 1.59–1.44 
(m, 2H) ppm. 13C NMR (101 MHz, CDCl3) δ = 178.12, 
155.40, 129.80, 115.56, 77.80, 55.81, 40.27, 37.07, 
35.10, 29.84, 26.12 ppm. FTIR (neat) ν = 3279, 2922, 
2867, 1640, 1513, 1451, 1241 cm-1. HR-MS (ESI): 
C16H23N2O2+ [M+H]+: calculated: 275.1754 found: 
275.1755. M.p. = 109–111°C. 
 
N-benzyltetrahydro-1H-pyrrolizine-7a(5H)-
carboxamide (21) 
Purification by column chromatography on basic alumin-
ium oxide using EtOAC:pentane = 1:3 (Rf  = 0.4). The 
product was obtained as a yellow oil in 71% yield (82 
mg, 0.34 mmol). 1H NMR (400 MHz, CDCl3) δ = 8.32 
(s, 1H), 7.38–7.23 (m, 5H), 4.42 (d, J = 6.0 Hz, 2H), 
3.10–3.00 (m, 2H), 2.63–2.52 (m, 2H), 2.29–2.20 (m, 
2H), 1.86–1.72 (m, 4H), 1.73–1.64 (m, 2H) ppm. 13C 
NMR (101 MHz, CDCl3) δ = 177.72, 139.15, 128.74, 
127.50, 127.31, 77.96, 55.94, 43.15, 37.35, 26.41 ppm. 
FTIR (neat) ν = 3322, 2961, 2868, 2362, 1667, 1508 cm-
1. HR-MS (ESI): C15H21N2O+ [M+H]+: calculated: 
245.1648 found: 245.1651. 
 
(S)-N-(1-Phenylethyl)tetrahydro-1H-pyrrolizine-
7a(5H)-carboxamide (22) 
Purification by column chromatography on silica gel 
using CH2Cl2:MeOH = 20:1 (Rf = 0.07). The product 
was obtained as a yellow oil in 69 % yield (69 mg, 0.33 
mmol, e.r. 99:1 by HPLC). 1H NMR (400 MHz, CDCl3) 
δ = 8.30 (d, J = 6.7 Hz, 1H), 7.37–7.20 (m, 5H), 5.06 
(dq, J = 13.9, 6.9 Hz, 1H), 3.14–3.01 (m, 2H), 2.64–2.53 
(m, 2H), 2.28–2.20 (m, 1H), 2.19–2.11 (m, 1H), 1.85–
1.63 (m, 6H), 1.47 (t, J = 6.3 Hz, 3H) ppm. 13C NMR 
(101 MHz, CDCl3) δ = 176.69, 144.08, 128.67, 127.10, 
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126.04, 77.88, 55.95, 47.98, 37.21, 37.19, 26.40, 22.47 
ppm. FTIR (neat) ν = 3313, 2965, 2868, 2361, 1669, 
1497 cm-1. HR-MS (ESI): C16H23N2O+ [M+H]+: calcu-
lated: 259.1805 found: 259.1805. [α]24D = -39.3° (c = 
1.12, CHCl3). Enantiomeric purity was determined by 
HPLC using a Chiracel 1A column (1 mLmin-1, 
iPrOH:n-hexane 3:97, UV 225 nm): major enantiomer: tR 
= 19.66 min, minor enantiomer tR = 26.93 min. 
 
Methyl-(hexahydro-1H-pyrrolizine-7a-carbonyl)-
tryptophanate (23) 
The reaction was performed using the general procedure 
on a 0.3 mmol scale. Purification by column chromatog-
raphy on silica gel using EtOAc:pentane = 3:1 (Rf = 
0.04). The product was obtained as a colorless oil in 
77 % yield (82 mg, 0.23 mmol , e.r. 53:47 by HPLC of 
the Boc-protected derivative). 1H NMR (500 MHz, 
CDCl3) δ = 8.46 (d, J = 8.6 Hz, 1H), 8.31 (s, 1H), 7.57 
(d, J = 7.8 Hz, 1H), 7.34 (d, J = 8.1 Hz, 1H), 7.20–7.14 
(m, 1H), 7.12–7.08 (m, 1H), 6.99 (d, J = 2.3 Hz, 1H), 
4.87 (dt, J = 8.8, 6.1 Hz, 1H), 3.68 (s, 3H), 3.31–3.27 
(m, 2H), 3.01–2.95 (m, 1H), 2.82–2.76 (m, 1H), 2.50–
2.40 (m, 2H), 2.20–2.12 (m, 1H), 2.05–1.97 (m, 1H), 
1.75––1.69 (m, 1H), 1.69–1.62 (m, 4H), 1.40 (m, 1H) 
ppm. 13C NMR (126 MHz, CDCl3) δ = 197.26, 182.60, 
177.84, 172.79, 136.20, 127.83, 122.62, 122.19, 119.57, 
118.75, 111.26, 110.69, 77.73, 55.82, 55.64, 52.77, 
52.32, 37.27, 36.89, 27.87, 26.28, 26.21 ppm. FTIR 
(neat) ν = 3261, 2957, 2923, 2852, 1744, 1646, 1506 
cm-1. HR-MS (ESI): C20H26N3O3+ [M+H]+: calculated: 
356.1969 found: 356.1972. The e.r. was determined by 
HPLC using a Chiracel OD-H column (0.5 mLmin-1, 
iPrOH:n-hexane 3:97, UV 225 nm): first enantiomer: tR 
= 41.83 min, second enantiomer tR = 61.73 min. 
 
Methyl-(hexahydro-1H-pyrrolizine-7a-carbonyl)-
valinate (24) 
Purification by column chromatography on silica gel 
using EtOAc:pentane = 1:1 (Rf = 0.05). The product was 
obtained as a colorless oil in 69 % yield (55 mg, 0.26 
mmol, e.r. 50:50 by HPLC). 1H NMR (400 MHz, CDCl3) 
δ = 8.48 (d, J = 8.9 Hz, 1H), 4.45 (dd, J = 9.6, 4.9 Hz, 
1H), 3.71 (s, 3H), 3.19–3.08 (m, 2H), 2.65–2.56 (m, 2H), 
2.23–2.13 (m, 3H), 1.83–1.69 (m, 6H), 0.92 (d, J = 6.8 
Hz, 3H), 0.88 (d, J = 6.9 Hz, 3H) ppm. 13C NMR (126 
MHz, CDCl3) δ = 177.80, 172.78, 77.95, 56.76, 55.88, 
55.86, 52.11, 37.33, 37.14, 31.21, 26.57, 26.42, 19.38, 
17.75 ppm. FTIR (neat) ν = 3322, 2961, 2932, 2870, 
1741, 1673, 1499 cm-1. HR-MS (ESI): C15H25N2O5+ 
[M+H]+: calculated: 269.1860 found: 269.1861. The e.r. 
was determined by HPLC using a Chiracel AD-H col-
umn (0.5 mLmin-1, iPrOH:n-hexane 5:95, UV 225 nm): 
first enantiomer: tR = 16.73 min, second enantiomer tR = 
20.13 min. 
 
Methyl-(hexahydro-1H-pyrrolizine-7a-carbonyl)-
phenylalaninate (25) 
Purification by column chromatography on silica gel 
using CH2Cl2:MeOH = 40:1 (Rf = 0.48). The product 
was obtained as a yellow oil in 63 % yield (94 mg, 0.3 
mmol, e.r. 53:47 by HPLC). 1H NMR (400 MHz, CDCl3) 
δ = 8.38 (d, J = 7.6 Hz, 1H), 7.35–7.18 (m, 3H), 7.17–
7.08 (m, 2H), 4.85–4.75 (m, 1H), 3.72 (s, 3H), 3.18 (dd, 
J = 13.9, 5.5 Hz, 1H), 3.10–3.04 (m, 1H), 3.03 (dd, J = 
13.9, 7.6 Hz, 1H), 2.98–2.88 (m, 1H), 2.57–2.46 (m, 
2H), 2.19–2.13 (m, 1H), 2.01–1.93 (m, 1H), 1.76–1.71 
(m, 1H), 1.70–1.63 (m, 4H), 1.51–1.40 (m, 1H) ppm. 13C 
NMR (101 MHz, CDCl3) δ = 172.40, 136.49, 129.35, 
128.54, 127.07, 77.81, 55.85, 55.73, 52.73, 52.33, 38.19, 
37.12, 36.97, 26.33, 26.23 ppm. FTIR (neat) ν = 3310, 
2955, 2869, 1744, 1669, 1502 cm-1. HR-MS (ESI): 
C18H25N2O3+ [M+H]+: calculated: 317.1860 found: 
317.1865. The e.r. was determined by HPLC using a 
Chiracel OD-H column (0.5 mLmin-1, iPrOH:n-hexane 
3:97, UV 225 nm): first enantiomer: tR = 48.25 min, 
second enantiomer tR = 58.35 min. 
 
Methyl-(hexahydro-1H-pyrrolizine-7a-carbonyl)-
methioninate (26) 
Purification by column chromatography on silica gel 
using CH2Cl2:MeOH = 20:1 (Rf = 0.38). The product 
was obtained as a yellow oil in 63 % yield (89 mg, 0.3 
mmol, e.r. 52:48 by HPLC). 1H NMR (400 MHz, CDCl3) 
δ = 8.49 (d, J = 9.1 Hz, 1H), 4.63 (td, J = 8.3, 5.0 Hz, 
1H), 3.73 (s, 3H), 3.19–3.06 (m, 2H), 2.65–2.56 (m, 2H), 
2.52–2.46 (m, 2H), 2.24–2.12 (m, 3H), 2.10 (s, 3H), 
2.02–1.91 (m, 1H), 1.88–1.78 (m, 2H), 1.78–1.63 (m, 
4H) ppm. 13C NMR (101 MHz, CDCl3) δ = 177.80, 
172.53, 77.70, 55.77, 55.76, 52.34, 51.09, 37.07, 31.98, 
30.24, 26.41, 26.24, 15.56 ppm. FTIR (neat) ν = 3305, 
2960, 2868, 1743, 1670, 1502, 1442, 1224, 1175 cm-1. 
HR-MS (ESI): C14H25N2O3S+ [M+H]+: calculated: 
301.1580 found: 301.1585. The e.r. was determined by 
HPLC using a Chiracel AD-H column (0.5 mLmin-1, 
iPrOH:n-hexane 5:95, UV 225 nm): first enantiomer: tR 
= 37.20 min, second enantiomer tR = 42.95 min. 
 
Dimethyl-(hexahydro-1H-pyrrolizine-7a-carbonyl)-
glutamate (27) 
The reaction was performed using the general procedure 
on a 0.3 mmol scale. Purification by column chromatog-
raphy on silica gel using EtOAc:pentane = 2:1 (Rf = 
0.05). The product was obtained as a yellow oil in 51 % 
yield (47 mg, 0.15 mmol , e.r. 57:43 by HPLC). 1H NMR 
(500 MHz, CDCl3) δ = 8.44 (d, J = 8.7 Hz, 1H), 4.53 (td, 
J = 8.8, 5.2 Hz, 1H), 3.72 (s, 3H), 3.67 (s, 3H), 3.17–
3.07 (m, 2H), 2.63–2.55 (m, 2H), 2.43–2.29 (m, 2H), 
2.27–2.20 (m, 1H), 2.20–2.11 (m, 2H), 2.01–1.92 (m, 
1H), 1.81–1.64 (m, 6H) ppm. 13C NMR (126 MHz, 
CDCl3) δ = 178.14, 173.14, 172.56, 77.80, 55.89, 55.84, 
52.48, 51.92, 51.25, 37.22, 37.18, 30.36, 27.58, 26.46, 
26.33 ppm. FTIR (neat) ν = 3261, 2957, 2923, 2852, 
1744, 1646, 1506, 1439 cm -1. HR-MS (ESI): 
C15H25N2O5+ [M+H]+: calculated: 313.1758 found: 
313.1762. The e.r. was determined by HPLC using a 
Chiracel AD-H column (0.5 mLmin-1, iPrOH:n-hexane 
5:95, UV 225 nm): first enantiomer: tR = 63.66 min, 
second enantiomer tR = 67.22 min. 
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2-(3-methylbut-2-en-1-yl)-N-phenylpyrrolidine-2-
carboxamide (Δ2,3) and 2-(3-methylbut-3-en-1-yl)-N-
phenylpyrrolidine-2-carboxamide (Δ3,4 ) (30 and 31) 
Imine (44 mg, 0.28 mmol, 1.00 equiv.) and isonitrile (29 
mg, 0.28 mmol, 1.00 equiv.) were dissolved in dry tolu-
ene (2 mL) and Et3N·HCl (77 mg, 0.56 mmol, 2.00 
equiv.) was added. The suspension was heated under 
reflux for 17 h and the reaction was monitored by TLC. 
The reaction mixture was diluted with water, the layers 
were separated and the aqueous layer was extracted us-
ing EtOAc (2x). The combined organic layers were dried 
over MgSO4. The solvents were removed in vacuo and 
the residue was purified by flash column chromatog-
raphy on silica gel using CH2Cl2:MeOH 40:1, 0.1% Et3N 
(Rf = 0.24). The two products (Δ2,3:Δ3,4 = 2.1 :1) were 
obtained as a yellow oil in 57% yield (41 mg, 0.16 
mmol). 
Δ2,3: 1H NMR (400 MHz, CDCl3) δ = 10.06 (bs, J = 12.0 
Hz, 1H), 7.66-7.58 (m, 2H), 7.37-7.27 (m, 2H), 7.12-
7.04 (m, 1H), 5.09 (tdt, J = 6.8, 2.9, 1.4 Hz, 1H), 3.16-
3.03 (m, 1H), 2.99-2.89 (m, 1H), 2.79-2.67 (m, 1H), 
2.44-2.32 (m, 1H), 2.28-2.20 (m, 1H), 1.86 – 1.73 (m, 
3H), 1.68 (d, J = 27.2 Hz, 6H) ppm. 13C NMR (101 
MHz, CDCl3) δ = 175.51, 138.28, 136.37, 129.04, 
123.85, 119.29, 118.78, 70.12, 47.34, 36.73, 36.14, 
26.56, 26.18, 18.14 ppm. 
Δ3,4: 1H NMR (400 MHz, CDCl3) δ = 10.06 (bs, J = 12.0 
Hz, 1H), 7.66-7.58 (m, 2H), 7.37-7.27 (m, 2H), 7.12-
7.04 (m, 1H), 4.73-4.65 (m, 2H), 3.16-3.03 (m, 1H), 
2.99-2.89 (m, 1H), 2.44-2.32 (m, 1H), 2.28-2.20 (m, 
1H), 2.02 (td, J = 9.8, 5.4 Hz, 2H), 1.86 – 1.73 (m, 4H), 
1.72 – 1.70 (m, 3H) ppm. 13C NMR (101 MHz, CDCl3) δ 
= 175.01, 145.29, 138.15, 129.07, 123.96, 119.32, 
110.33, 70.50, 47.34, 37.39, 37.21, 33.20, 26.33, 22.75 
ppm. FTIR (neat) ν = 3244, 2967, 2872, 1681, 1600, 
1516, 1441, 1310, 755 cm-1. HR-MS (ESI): C16H23N2O+ 
[M+H]+: calculated: 259.1805 found: 259.1809. 
 
3-Oxo-N-phenyltetrahydro-1H-pyrrolizine-7a(5H)-
carboxamide (32) 
Pyrrolizidine 18 (15 mg, 65 µmol, 1.00 equiv.) was dis-
solved in anhydrous CH2Cl2 (1.0 mL) under argon at-
mosphere. Benzyl(triethyl)ammonium permanganate 
(61 mg, 0.195 mmol, 3.00 equiv.) was added and the 
suspension was stirred for 24 h at room temperature. 
Conversion was monitored by GC-MS. The suspension 
was filtered over cotton and the filtrate was transferred 
to a separation funnel. The solution was washed with 
water, the layers were separated and the aqueous layer 
was extracted with CH2Cl2 (2x). The combined organic 
layers were dried over MgSO4 and the solvent was evap-
orated. The crude extracts were purified by column 
chromatography on silica gel using CH2Cl2:MeOH = 
30:1 (Rf = 0.2). The product was obtained as a white 
solid in 73% yield (11.6 mg, 47 µmol). 1H NMR (400 
MHz, CDCl3) δ = 8.15 (s, 1H), 7.62 –7.54 (m, 2H), 
7.40–7.31 (m, 2H), 7.19–7.12 (m, 1H), 3.86–3.75 (m, 
1H), 3.21 (ddt, J = 12.3, 8.3, 4.5 Hz, 1H), 2.82 (dt, J = 
17.1, 10.2 Hz, 1H), 2.68–2.57 (m, 2H), 2.50 (ddd, J = 
17.1, 9.5, 2.4 Hz, 1H), 2.30–2.16 (m, 1H), 2.12–1.94 (m, 
2H), 1.82–1.70 (m, 1H) ppm. 13C NMR (101 MHz, 
CDCl3) δ = 179.17, 172.36, 137.18, 129.27, 125.11, 
120.05, 75.23, 43.92, 36.60, 33.58, 32.23, 26.02 ppm. 
FTIR (neat) ν = 3293, 2953, 1676, 1598, 1532, 1441 
cm-1. HR-MS (ESI): C14H17N2O2+ [M+H]+: calculated: 
245.1285 found: 245.1281. M.p. = 172°C. 
 
7a-(Phenylcarbamoyl)hexahydropyrrolizine-4(1H)-
oxide (33) 
To a solution of pyrrolizidine 18 (10 mg, 43 µmol, 1.00 
equiv.) in anhydrous CH2Cl2 (0.22 mL) at 0°C was add-
ed a solution of m-CPBA (12 mg, 43 µmol, 1.00 equiv.) 
in anhydrous CH2Cl2 (0.22 mL). The solution was stirred 
at 0°C and completion was monitored on TLC 
(CH2Cl2:MeOH = 40:1). After 5 h, the reaction mixture 
was quenched with sat. aqueous Na2CO3 solution. The 
mixture was diluted with Et2O and transferred to a sepa-
ration funnel. The organic layer was washed with 
Na2CO3 solution, the layers were separated and the or-
ganic layer was dried over MgSO4. The crude extracts 
were purified by column chromatography on basic alu-
minum oxide using CH2Cl2:MeOH 100:1 as an eluent 
(Rf = 0.16). The product was obtained as a colorless oil 
in 82% yield (8.8 mg, 36 µmol). 1H NMR (400 MHz, 
CDCl3) δ = 14.60 (s, 1H), 7.62 (dd, J = 8.2, 1.1 Hz, 2H), 
7.35–7.25 (m, 2H), 7.07 (td, J = 7.3, 1.2 Hz, 1H), 3.87–
3.76 (m, 2H), 3.76–3.66 (m, 2H), 2.97–2.86 (m, 2H), 
2.38–2.25 (m, 2H), 2.18–2.00 (m, 4H) ppm. 13C NMR 
(101 MHz, CDCl3) δ = 167.96, 138.52, 128.98, 124.09, 
120.43, 83.53, 68.40, 32.97, 19.87 ppm. FTIR (neat) ν = 
3386, 3270, 2922, 1661, 1596, 1556, 1495, 1449 cm-1. 
HR-MS (ESI): C14H19N2O2+ [M+H]+: calculated: 
247.1441 found: 247.1444. 
 
N-((Tetrahydro-1H-pyrrolizin-7a(5H)-
yl)methyl)aniline (34) 
In a two-neck roundbottom flask equipped with a reflux 
condenser, pyrrolizidine 18 (65 mg, 0.28 mmol, 1 equiv.) 
in toluene (3 mL) was dissolved under argon and the 
solution was cooled to 0°C. Red-Al®-solution (0.73 mL, 
2.26 mmol, 60% in toluene) was added dropwise. The 
cooling bath was removed after addition and the reaction 
mixture was heated to reflux for 15 h. The reaction mix-
ture was cooled to 0°C and aqueous NaOH (c = 3 mol·L-
1, 6.5 mL) was added carefully. The reaction mixture was 
stirred at room temperature overnight. The reaction mix-
ture was transferred into a separation funnel and diluted 
with ether. The aqueous layer was separated and the 
organic layer was washed with 10% NaOH solution and 
brine. The organic layer was dried over MgSO4 and the 
solvent was evaporated to give the product as a pale 
yellow oil in 99% yield (60.7 mg, 0.28 mmol). 1H NMR 
(400 MHz, methanol-d4) δ = 7.12–7.05 (m, 2H), 6.67–
6.62 (m, 2H), 6.62–6.57 (m, 1H), 3.07–3.00 (m, 2H), 
3.03 (s, 2H), 2.74–2.66 (m, 2H), 2.00–1.93 (m, 2H), 
1.92–1.85 (m, 2H), 1.82–1.74 (m, 2H), 1.72–1.66 (m, 
2H) ppm. 13C NMR (101 MHz, methanol-d4) δ = 150.68, 
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130.03, 117.94, 113.83, 56.41, 53.52, 37.32, 25.77 ppm. 
FTIR (neat) ν = 3360, 2953, 2865, 2357, 1604, 1504, 
1315, 1260 cm-1. HR-MS (ESI): C14H21N2+ [M+H]+: 
calculated: 217.1699 found 217.1703. 
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